Home » Soligenix Granted US Patent for Treatment of Irritable Bowel Syndrome
Soligenix Granted US Patent for Treatment of Irritable Bowel Syndrome
Soligenix, a late-stage biopharmaceutical company, announced Wednesday that the United States Patent Office has issued a patent (US 7,704,985) titled “Treatment of Irritable Bowel Syndrome and Related Bowel Diseases.”
Forbes
Forbes
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May